drugset / Trial / NCT02792465
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1 study of investigational agent CFI-402257 in patients with advanced cancer. The purpose of this study is to see how safe and tolerable CFI-402257 is in cancer patients as well as the pharmacokinetics (PK). This study is the first time that CFI-402257 is given to humans.
Timeline
- Start
- 2016-11-11
- Primary completion
- 2025-06-12
- Completion
- 2025-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUVIXASERTIB | Small molecule | 168 mg | Oral |
| Background | Fulvestrant | Small molecule | — | Other |